Amneal Receives FDA Approval for Two Biosimilars
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 23 2025
0mins
Should l Buy AMRX?
Source: NASDAQ.COM
- Biosimilar Approval: Amneal Pharmaceuticals announced FDA approval for its biosimilars Boncresa and Oziltus, referencing Prolia and XGEVA, with plans to commercialize six biosimilars by 2027, significantly enhancing the company's competitive edge in the biopharmaceutical market.
- Market Potential: According to IQVIA, annual U.S. sales for Amgen's Prolia and XGEVA were approximately $5.3 billion for the 12 months ending October 2025, indicating substantial commercial opportunities in the biosimilar market.
- Strategic Partnership: Amneal's collaboration with Spain-based mAbxience, responsible for the development and manufacturing of Denosumab while Amneal holds exclusive U.S. commercialization rights, will further solidify its market position.
- Long-term Growth Outlook: Amneal's co-CEOs stated that biosimilars represent the next wave of affordable medicines in the U.S., and the addition of two denosumab biosimilars will strengthen their position in this rapidly growing category, serving as a key driver for sustainable growth.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy AMRX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on AMRX
Wall Street analysts forecast AMRX stock price to rise
3 Analyst Rating
3 Buy
0 Hold
0 Sell
Strong Buy
Current: 13.250
Low
13.00
Averages
14.33
High
15.00
Current: 13.250
Low
13.00
Averages
14.33
High
15.00
About AMRX
Amneal Pharmaceuticals, Inc. is a global pharmaceutical company, which develops, manufactures, markets and distributes a portfolio of essential medicines. Its Affordable Medicines segment includes a portfolio of over 280 product families covering a range of dosage forms and delivery systems, including both immediate and extended-release oral solids, powders, liquids, sterile injectables, nasal sprays, inhalation and respiratory products, biosimilar products, ophthalmic, films, transdermal patches and topicals. Its Specialty segment is engaged in the development, promotion, sale and distribution of branded pharmaceutical products, with a focus on products addressing central nervous system disorders, including Parkinson’s disease and endocrine disorders. Its AvKARE segment provides pharmaceuticals, medical and surgical products and services primarily to governmental agencies, predominantly focused on the U.S. Department of Defense and the U.S. Department of Veterans Affairs.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Amneal Pharmaceuticals Reports Strong Q4 2025 Earnings Growth and Strategic Outlook
- Significant Revenue Growth: Amneal Pharmaceuticals reported Q4 2025 revenues of $814 million, an 11% increase year-over-year, with total annual revenue reaching $3 billion, underscoring the company's strong performance in complex generics and injectables, thereby solidifying its leadership in the U.S. affordable medicines market.
- Adjusted EBITDA Increase: The adjusted EBITDA for Q4 grew by 13% to $175 million, with a full-year adjusted EBITDA of $688 million, reflecting the company's success in operational efficiency and cost control, which is expected to support future profitability.
- New Product Launches and Market Opportunities: The specialty therapy CREXONT reached 23,000 patients with over 3% market share, with expectations to double revenue in 2026, highlighting the company's potential in new product development and market penetration.
- Optimistic Future Outlook: Management forecasts total revenue for 2026 to be between $3.05 billion and $3.15 billion, representing growth of 1% to 4%, emphasizing that growth in the Affordable Medicines segment will be driven by new product approvals, showcasing confidence in future performance.
See More
Amneal Pharmaceuticals Q4 Earnings Beat Expectations with Strong Revenue Growth
- Strong Financial Performance: Amneal Pharmaceuticals reported fourth-quarter revenue of $814.32 million, an 11% year-over-year increase that surpassed the market expectation of $807.89 million, indicating robust market performance.
- Improved Profitability: The adjusted earnings per share reached 21 cents, exceeding Wall Street's estimate of 18 cents, reflecting the company's success in cost control and product mix optimization.
- Significant EBITDA Growth: Adjusted EBITDA for the fourth quarter was $175 million, a 13% increase year-over-year, demonstrating ongoing improvements in operational efficiency and profitability.
- Positive Future Outlook: The company expects fiscal 2026 adjusted earnings between 93 cents and $1.03, with sales projected at $3.05 to $3.15 billion, although slightly below consensus, still indicating solid growth potential.
See More
Amneal Pharmaceuticals Q4 Earnings Exceed Expectations
- Strong Earnings Report: Amneal Pharmaceuticals reported a Q4 non-GAAP EPS of $0.21, beating expectations by $0.03, indicating sustained improvement in profitability and boosting investor confidence.
- Revenue Growth: The company achieved $814 million in revenue for Q4, an 11.4% year-over-year increase that surpassed market expectations by $6.68 million, reflecting strong demand for its product portfolio and an increase in market share.
- Future Guidance: Amneal projects net revenue for 2026 to be between $3.05 billion and $3.15 billion, with adjusted EBITDA expected to be between $720 million and $760 million, demonstrating confidence in future growth.
- Earnings Per Share Outlook: The company anticipates adjusted diluted EPS for 2026 to range from $0.93 to $1.03, indicating further enhancement in profitability, which may attract more investor interest.
See More
Amneal Pharmaceuticals Set to Release Q4 Earnings on February 27
- Earnings Announcement: Amneal Pharmaceuticals is set to announce its Q4 earnings on February 27 before market open, with consensus EPS estimate at $0.18, reflecting a 50% year-over-year increase, and revenue estimate at $807.32 million, indicating a 10.4% year-over-year growth, showcasing the company's ongoing potential for revenue and profitability growth.
- Historical Performance: Over the past two years, Amneal has successfully beaten EPS estimates 88% of the time and revenue estimates 63% of the time, indicating the company's reliability in financial forecasting and bolstering market confidence.
- Estimate Revision Trends: In the last three months, EPS estimates have seen one upward revision and one downward revision, while revenue estimates have experienced one upward and two downward revisions, reflecting a cautious market sentiment and uncertainty regarding the company's future performance.
- Market Position Enhancement: Amneal's inclusion in the S&P SmallCap 600 index signifies an elevation in its market recognition and influence, potentially attracting more investor attention and enhancing its stock performance.
See More
Doseology Sciences Launches New Energy Product Line
- Market Trend Analysis: The global health and wellness sector is projected to reach $6 trillion in consumer spending by 2026, driven by rising demand for functional products, compelling companies to adapt to the FDA's updated 'Healthy' labeling framework to meet market needs.
- New Product Launch: Doseology Sciences launched caffeine-based energy pouches in January 2026, marking the entry of its Feed That Brain brand into the rapidly growing oral pouch market, utilizing a sugar-free, non-carbonated, portable design to cater to consumer demand for healthier alternatives.
- Strategic Acquisition: Doseology acquired the Feed That Brain brand for $400,000 in August 2025, enhancing its competitive edge in the functional product space, while also appointing Joseph Mimran as a strategic advisor to further bolster brand influence.
- Optimistic Market Outlook: The global energy drinks market is expected to grow from $79.4 billion in 2024 to $125.1 billion by 2030, indicating strong market demand, and Doseology's product innovations align perfectly with this trend, likely driving future company growth.
See More
Doseology Sciences Launches New Energy Product Line
- Market Trend Analysis: The global health and wellness sector is projected to reach $6 trillion in consumer spending by 2026, driven by rising demand for functional products, compelling companies to adapt to the FDA's new labeling framework to meet consumer preferences for sugar-free and preservative-free options, thereby enhancing market competitiveness.
- New Product Launch: Doseology Sciences initiated pilot production of caffeine-based energy pouches in January 2026, marking the entry of its Feed That Brain brand into the rapidly growing oral pouch market, which is expected to attract consumers seeking portable energy supplements.
- Strategic Acquisition: Doseology acquired the Feed That Brain brand for $400,000 in August 2025, leveraging its strengths in functional product design to drive compliant new product development and further expand market share.
- Market Potential: The global energy drinks market is expected to grow from $79.4 billion in 2024 to $125.1 billion by 2030, indicating strong market demand, and Doseology's product innovations align perfectly with this trend, likely driving future growth for the company.
See More
Amneal Pharmaceuticals Reports Strong Q4 2025 Earnings Growth and Strategic Outlook
- Significant Revenue Growth: Amneal Pharmaceuticals reported Q4 2025 revenues of $814 million, an 11% increase year-over-year, with total annual revenue reaching $3 billion, underscoring the company's strong performance in complex generics and injectables, thereby solidifying its leadership in the U.S. affordable medicines market.
- Adjusted EBITDA Increase: The adjusted EBITDA for Q4 grew by 13% to $175 million, with a full-year adjusted EBITDA of $688 million, reflecting the company's success in operational efficiency and cost control, which is expected to support future profitability.
- New Product Launches and Market Opportunities: The specialty therapy CREXONT reached 23,000 patients with over 3% market share, with expectations to double revenue in 2026, highlighting the company's potential in new product development and market penetration.
- Optimistic Future Outlook: Management forecasts total revenue for 2026 to be between $3.05 billion and $3.15 billion, representing growth of 1% to 4%, emphasizing that growth in the Affordable Medicines segment will be driven by new product approvals, showcasing confidence in future performance.
See More
Amneal Pharmaceuticals Q4 Earnings Beat Expectations with Strong Revenue Growth
- Strong Financial Performance: Amneal Pharmaceuticals reported fourth-quarter revenue of $814.32 million, an 11% year-over-year increase that surpassed the market expectation of $807.89 million, indicating robust market performance.
- Improved Profitability: The adjusted earnings per share reached 21 cents, exceeding Wall Street's estimate of 18 cents, reflecting the company's success in cost control and product mix optimization.
- Significant EBITDA Growth: Adjusted EBITDA for the fourth quarter was $175 million, a 13% increase year-over-year, demonstrating ongoing improvements in operational efficiency and profitability.
- Positive Future Outlook: The company expects fiscal 2026 adjusted earnings between 93 cents and $1.03, with sales projected at $3.05 to $3.15 billion, although slightly below consensus, still indicating solid growth potential.
See More
Amneal Pharmaceuticals Q4 Earnings Exceed Expectations
- Strong Earnings Report: Amneal Pharmaceuticals reported a Q4 non-GAAP EPS of $0.21, beating expectations by $0.03, indicating sustained improvement in profitability and boosting investor confidence.
- Revenue Growth: The company achieved $814 million in revenue for Q4, an 11.4% year-over-year increase that surpassed market expectations by $6.68 million, reflecting strong demand for its product portfolio and an increase in market share.
- Future Guidance: Amneal projects net revenue for 2026 to be between $3.05 billion and $3.15 billion, with adjusted EBITDA expected to be between $720 million and $760 million, demonstrating confidence in future growth.
- Earnings Per Share Outlook: The company anticipates adjusted diluted EPS for 2026 to range from $0.93 to $1.03, indicating further enhancement in profitability, which may attract more investor interest.
See More
Amneal Pharmaceuticals Set to Release Q4 Earnings on February 27
- Earnings Announcement: Amneal Pharmaceuticals is set to announce its Q4 earnings on February 27 before market open, with consensus EPS estimate at $0.18, reflecting a 50% year-over-year increase, and revenue estimate at $807.32 million, indicating a 10.4% year-over-year growth, showcasing the company's ongoing potential for revenue and profitability growth.
- Historical Performance: Over the past two years, Amneal has successfully beaten EPS estimates 88% of the time and revenue estimates 63% of the time, indicating the company's reliability in financial forecasting and bolstering market confidence.
- Estimate Revision Trends: In the last three months, EPS estimates have seen one upward revision and one downward revision, while revenue estimates have experienced one upward and two downward revisions, reflecting a cautious market sentiment and uncertainty regarding the company's future performance.
- Market Position Enhancement: Amneal's inclusion in the S&P SmallCap 600 index signifies an elevation in its market recognition and influence, potentially attracting more investor attention and enhancing its stock performance.
See More
Doseology Sciences Launches New Energy Product Line
- Market Trend Analysis: The global health and wellness sector is projected to reach $6 trillion in consumer spending by 2026, driven by rising demand for functional products, compelling companies to adapt to the FDA's updated 'Healthy' labeling framework to meet market needs.
- New Product Launch: Doseology Sciences launched caffeine-based energy pouches in January 2026, marking the entry of its Feed That Brain brand into the rapidly growing oral pouch market, utilizing a sugar-free, non-carbonated, portable design to cater to consumer demand for healthier alternatives.
- Strategic Acquisition: Doseology acquired the Feed That Brain brand for $400,000 in August 2025, enhancing its competitive edge in the functional product space, while also appointing Joseph Mimran as a strategic advisor to further bolster brand influence.
- Optimistic Market Outlook: The global energy drinks market is expected to grow from $79.4 billion in 2024 to $125.1 billion by 2030, indicating strong market demand, and Doseology's product innovations align perfectly with this trend, likely driving future company growth.
See More
Doseology Sciences Launches New Energy Product Line
- Market Trend Analysis: The global health and wellness sector is projected to reach $6 trillion in consumer spending by 2026, driven by rising demand for functional products, compelling companies to adapt to the FDA's new labeling framework to meet consumer preferences for sugar-free and preservative-free options, thereby enhancing market competitiveness.
- New Product Launch: Doseology Sciences initiated pilot production of caffeine-based energy pouches in January 2026, marking the entry of its Feed That Brain brand into the rapidly growing oral pouch market, which is expected to attract consumers seeking portable energy supplements.
- Strategic Acquisition: Doseology acquired the Feed That Brain brand for $400,000 in August 2025, leveraging its strengths in functional product design to drive compliant new product development and further expand market share.
- Market Potential: The global energy drinks market is expected to grow from $79.4 billion in 2024 to $125.1 billion by 2030, indicating strong market demand, and Doseology's product innovations align perfectly with this trend, likely driving future growth for the company.
See More
